XSPRAY PHARMA AB (PUBL)

About

Xspray Pharma AB is a Swedish pharmaceutical company based in Solna, Stockholm. Founded in 2003, it specializes in developing innovative, patented amorphous product candidates using its proprietary HyNap technology. This technology enhances marketed protein kinase inhibitors (PKIs) for cancer treatment, addressing issues like low solubility and variability in drug uptake. The company is focused on creating improved versions of existing PKIs, with its lead product candidate, Dasynoc® (dasatinib), targeting chronic myeloid leukemia (CML). Dasynoc® is nearing US commercialization, pending FDA approval expected in 2025. Xspray also has a second candidate, XS003 (nilotinib), with a New Drug Application accepted by the FDA. The company aims to launch multiple products and has a robust pipeline targeting over 80 approved US PKIs, all while prioritizing patient quality of life through superior drug profiles.